You are here » Home » Companies » Company Overview » Avon Lifesciences Ltd

Avon Lifesciences Ltd.

BSE: 531541 Sector: Industrials
NSE: N.A. ISIN Code: INE881A01015
BSE LIVE 14:56 | 02 Dec 12.22 0.53
(4.53%)
OPEN

11.99

HIGH

12.22

LOW

11.80

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 11.99
PREVIOUS CLOSE 11.69
VOLUME 21388
52-Week high 48.80
52-Week low 6.40
P/E
Mkt Cap.(Rs cr) 29.12
Buy Price 12.22
Buy Qty 35178.00
Sell Price 0.00
Sell Qty 0.00
OPEN 11.99
CLOSE 11.69
VOLUME 21388
52-Week high 48.80
52-Week low 6.40
P/E
Mkt Cap.(Rs cr) 29.12
Buy Price 12.22
Buy Qty 35178.00
Sell Price 0.00
Sell Qty 0.00

Avon Lifesciences Ltd. (AVONLIFESCIENCE) - Company History

Avon Organics, promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu was incorporated in August 1993 to manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US. XTP shall be the technical supervisor for the transfer of technology, while SMEC shall supply the technical knowhow. The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA, MMAE, DEA, EEAA and Aralydes. The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Technology, where the value addition is high. To part finance its biotech project the company has made a preferential issue of 1800000 Equity shares at Rs. 38.75 each aggregating to Rs. 697.50 lacs and issued 400000 warrants convertible into 400000 equity shares during the year 1999-2000. The Bio-Technology Plant is located at Solapur,Maharashtra for manufacture of Ephedrine and Pseudo-Ephedrine with an installed capacity of 150 MT p.a. The plant has commenced operations during April 2001. The biotech division produces Pharmaceutical intermediates i.e Pseudoephedrine and ephedrine. The company has signed two longterm export contracts to supply fixed quantities of Pseudoephedrine and is in talks with a few more MNC's for long term contracts during the year 2001-02. The company's bio-tech division is pursuing USFD approval which will enable it to enter into regulated markets. The company is all set to introduce two high value added intermediates in its Diketene division.The company has already completed trial production for these two pharmaceutical products and is ready for commercial launch.The company is expected an additional turnover of Rs.12 crores from these products from the year 2005-06.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard